Clinical trial
Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study
NCT03674099 is registered in ClinicalTrials.gov with Tomas Olsson as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study
- Lead sponsor
- Tomas Olsson
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 1, 2018
- Completion date
- July 30, 2023
- Enrollment
- 200 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.